Published in Heart on June 01, 2005
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis (2012) 2.00
Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis (2011) 1.94
Impairment of coronary endothelial cell ET(B) receptor function after short-term inhalation exposure to whole diesel emissions. Am J Physiol Regul Integr Comp Physiol (2009) 1.17
Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol (2012) 1.17
Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol (2006) 1.13
Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol (2011) 1.01
The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br J Pharmacol (2013) 1.00
Regulation of vascular contractility and blood pressure by the E2F2 transcription factor. Circulation (2009) 0.93
Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.92
The influence of heart failure self-care on health outcomes: hypothetical cardioprotective mechanisms. J Cardiovasc Nurs (2009) 0.90
Endothelin-1 and the kidney--beyond BP. Br J Pharmacol (2012) 0.88
Pulmonary Hypertension and Cardiopulmonary Exercise in Heart Failure. Pulse (Basel) (2014) 0.84
ETA selective receptor antagonism prevents ventricular remodeling in volume-overloaded rats. Am J Physiol Heart Circ Physiol (2009) 0.83
Blockade of endothelin-1 with a novel series of 1,3,6-trisubstituted-2-carboxy-quinol-4-ones controls infection-associated preterm birth. Am J Pathol (2010) 0.82
MicroRNA and Heart Failure. Int J Mol Sci (2016) 0.81
Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart (2007) 0.79
Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors. PPAR Res (2014) 0.78
Changes of serum neurohormone after renal sympathetic denervation in dogs with pacing-induced heart failure. Int J Clin Exp Med (2014) 0.78
Successful drug development despite adverse preclinical findings part 2: examples. J Toxicol Pathol (2010) 0.78
The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1. Br J Pharmacol (2007) 0.77
Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System. Cardiovasc Toxicol (2016) 0.76
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (1994) 4.90
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med (1998) 2.90
Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol (2001) 2.58
Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest (1995) 1.95
Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature (1996) 1.73
Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest (2000) 1.65
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 1.61
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 1.51
Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens (1998) 1.48
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation (2004) 1.27
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 1.21
Endothelin antagonists. Lancet (1999) 1.20
Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol (1996) 1.07
Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation (1999) 0.97
Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 0.94
Endothelin in renal pathophysiology: from experimental to therapeutic application. Kidney Int (1996) 0.88
Endothelin-converting enzyme inhibitors: current status and perspectives. J Cardiovasc Pharmacol (2000) 0.86
Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens (1998) 4.94
Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (1994) 4.90
Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin during formation and disassembly of adhesions in migrating cells. J Cell Biol (2001) 3.99
The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol (2000) 3.43
Core content of a course in clinical pharmacology. Br J Clin Pharmacol (1997) 2.99
Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) (1983) 2.90
Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens (1993) 2.59
Ultrasonic hydrophone based on short in-fiber bragg gratings. Appl Opt (1998) 2.35
Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol (1999) 2.35
The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) (1993) 2.18
Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol (2001) 1.97
Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. Br J Clin Pharmacol (1993) 1.85
Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM (2000) 1.84
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol (2001) 1.77
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
Cardiovascular effects of particulate air pollution exposure: time course and underlying mechanisms. J Intern Med (2012) 1.68
Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol (1989) 1.68
Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) (2003) 1.66
Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest (1997) 1.65
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 1.61
L-NMMA increases blood pressure in man. Lancet (1993) 1.60
Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study. BMJ (1998) 1.60
Developing a core curriculum in clinical pharmacology and therapeutics: a Delphi study. Br J Clin Pharmacol (1997) 1.58
Secondhand smoke exposure and survival following acute coronary syndrome: prospective cohort study of 1261 consecutive admissions among never-smokers. Heart (2009) 1.57
Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J (2013) 1.55
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart (2006) 1.55
Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing percutaneous coronary intervention. Heart (2009) 1.54
Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin Radiol (2003) 1.52
Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J (2002) 1.52
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci (2001) 1.52
Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. Cardiovasc Res (2002) 1.51
Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens (1998) 1.48
Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 1.47
32-km distributed temperature sensor based on Brillouin loss in an optical fiber. Opt Lett (1993) 1.46
Aortic pulse-wave velocity. Lancet (1999) 1.45
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation (1999) 1.40
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol (2007) 1.38
Transversal and longitudinal images from the retina of the living eye using low coherence reflectometry. J Biomed Opt (1998) 1.36
Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology (2006) 1.34
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol (1989) 1.32
Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation (1995) 1.31
Blood glucose monitors: a laboratory and patient assessment. Br Med J (1980) 1.30
Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation (2010) 1.28
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J (1999) 1.28
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Clin Sci (Lond) (1997) 1.27
Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med (2002) 1.24
Direct measurement of intracellular pH changes in Xenopus eggs at fertilization and cleavage. J Cell Biol (1981) 1.23
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 1.21
Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol (1998) 1.21
Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab (1995) 1.19
Measurement of plasma angiotensin II. Clin Sci (Lond) (1985) 1.19
31P NMR reveals increased intracellular pH after fertilization in Xenopus eggs. Proc Natl Acad Sci U S A (1981) 1.18
An electrical block is required to prevent polyspermy in eggs fertilized by natural mating of Xenopus laevis. Dev Biol (1982) 1.18
Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax (2007) 1.17
Simultaneous en-face imaging of two layers in the human retina by low-coherence reflectometry. Opt Lett (1997) 1.17
Pulse transit time measured from the ECG: an unreliable marker of beat-to-beat blood pressure. J Appl Physiol (1985) (2005) 1.16
Peripheral endothelial dysfunction in normal pressure glaucoma. Invest Ophthalmol Vis Sci (1999) 1.16
Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun (2000) 1.16
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology (2000) 1.14
A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol Assess (2009) 1.13
The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther (1996) 1.12
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation (1998) 1.11
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation (1996) 1.11
Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem (1994) 1.11
Prevention of cardiac complications of non-cardiac surgery: stenosis and thrombosis. Br J Anaesth (2004) 1.09
Continuous positive airway pressure improves vascular function in obstructive sleep apnoea/hypopnoea syndrome: a randomised controlled trial. Thorax (2008) 1.08
Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol (2001) 1.08
Scottish Medicines Consortium: an overview of rapid new drug assessment in Scotland. Scott Med J (2007) 1.08
Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens (2000) 1.07
Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis (2004) 1.05
Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol (2001) 1.05
Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation (2004) 1.05
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res (1998) 1.04
Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut (2003) 1.04
Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation (2000) 1.03
Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol (1997) 1.03
Fertilization potential and electrical properties of the Xenopus laevis egg. Dev Biol (1985) 1.02
Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol (1998) 1.02
Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology (2001) 1.01
Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart (2004) 1.01
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart (2005) 1.01
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol (1997) 1.01
An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost (1997) 1.00
Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM (2009) 1.00
Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension (1998) 0.99
Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation (1991) 0.99
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation (1998) 0.99
Coherence imaging by use of a Newton rings sampling function. Opt Lett (1996) 0.98
Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol (1995) 0.98